Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc.

PLXNYSE / NASDAQHealthcareSmall cap

$2.90-$0.16 (-5.2%)

Last close · Data as of Nov 20, 2026

Market cap
$161.9M
Revenue
$52.7M
Net margin
-12.5%
ROCE
-9.2%

+66.7% over the last year

Protalix BioTherapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+9.8%
3M
+21.8%
6M
+44.3%
1Y
+66.7%
5Y
+195.9%

52-week range

Day change -$0.16 (-5.2%) from $3.06 to $2.90 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PLX, bought on each weekday since 2021.

News & filings

What Protalix BioTherapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 6.6 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 2.51 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Read moreShow less

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Sector
Healthcare
Shares outstanding
80.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$161.9M
P/B
3.4x
EV / Sales
2.7x
P/S
3.1x
52-week high
$3.15
52-week low
$1.67

Profitability

Operating margin
-10.4%
Net margin
-12.5%
EBITDA margin
-5.6%
ROE
-13.7%
ROCE
-9.2%
ROIC
-8.3%
ROA
-8.0%
Asset turnover
0.64

Growth

Revenue
$52.7M
Revenue growth, 1Y
-1.2%
Revenue CAGR, 3Y
3.5%
Net profit growth, 1Y
-325.2%
Free cash flow
-$13.6M

Solvency

Current ratio
2.51
Debt / Equity
0.17
Debt / Assets
0.10
CFO / Net profit
1.82
Cash / Market cap
18.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$52.7M
Cost of revenue$27.0M
Gross profit$25.8M
Operating expenses$31.3M
Research and development$19.6M
Selling, general and administrative$11.7M
Operating income-$5.5M
Interest and other-$110.0k
Pretax income-$5.6M
Tax and other$990.0k
Net income-$6.6M

Revenue and net profit

Revenue fell 1.2% in FY2025; net profit is the dashed line.

Protalix BioTherapeutics, Inc. revenue and net profit by fiscal year
Protalix BioTherapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$47.6M-$14.9M
FY2023$65.5M$8.3M
FY2024$53.4M$2.9M
FY2025$52.7M-$6.6M

Cash flows

FY2025: -$12.0M from operations, -$13.6M free after investment (dashed).

Protalix BioTherapeutics, Inc. operating and free cash flow by fiscal year
Protalix BioTherapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$25.0M-$25.6M
FY2023-$1.3M-$2.5M
FY2024$8.7M$7.4M
FY2025-$12.0M-$13.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$52.7M-1.2%1Y
EBITDA
-$3.0M-145.3%1Y
Net profit
-$6.6M-325.2%1Y
Cash from operations
-$12.0M-238.3%1Y
Free cash flow
-$13.6M-284.4%1Y
Revenue CAGR, 3Y
3.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$52.7M-$3.0M-$6.6M-$13.6M-13.7%-1.2%-325.2%

Monthly returns

Month-by-month returns of PLX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$82.3M
Liabilities$34.1M
Equity$48.2M
Paid-in capital$433.1M
Retained earnings-$385.0M

Market cap against peers

8 peers: same sector, nearest by size.

  1. Protalix BioTherapeutics, Inc. (this company)$161.9M
  2. CVRx, Inc.$156.0M

Peers map

Healthcare companies placed by value, growth and quality; PLX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Protalix BioTherapeutics, Inc. (this company)2.7x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Protalix BioTherapeutics, Inc.PLXthis company$161.9M—3.4x-13.7%—
Quanterix CorporationQTRX$179.0M-1.7x0.6x-36.2%-2.1x
Journey Medical CorporationDERM$171.3M-15.0x5.4x-35.9%-51.9x
Inogen, Inc.INGN$170.8M-7.5x0.9x-11.8%-8.9x
ADC Therapeutics SAADCT$167.9M-1.2x-0.9x76.7%-0.3x
Korro Bio, Inc.KRRO$161.2M-1.4x3.1x-228.0%-2.2x
CVRx, Inc.CVRX$156.0M—4.0x-135.6%—
Nano-X Imaging Ltd.NNOX$144.1M-1.9x1.0x-53.7%-2.1x
Health Catalyst, Inc.HCAT$143.4M-0.8x0.6x-72.4%-2.6x
Peer median—-1.7x1.0x-45.0%-2.2x

Year-to-date ROI

PLX since 1 January, against earlier years.

Historical volatility

PLX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Protalix BioTherapeutics, Inc. operating margin by fiscal year
Protalix BioTherapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-27.3%
FY202316.0%
FY20247.3%
FY2025-10.4%
LineFY2025
Cost of revenueCost Of Revenue$27.0M
Gross profitGross Profit$25.8M
Operating expensesOperating Expense$31.3M
Research and developmentResearch And Development$19.6M
Selling, general and administrativeSelling General And Administration$11.7M
Total expensesTotal Expenses$58.2M
Pretax incomePretax Income-$5.6M

Learn while you research

Academy chapters picked for Protalix BioTherapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →